NO871581L - Synergistisk kombinasjon av amantadin og selegilin. - Google Patents

Synergistisk kombinasjon av amantadin og selegilin.

Info

Publication number
NO871581L
NO871581L NO871581A NO871581A NO871581L NO 871581 L NO871581 L NO 871581L NO 871581 A NO871581 A NO 871581A NO 871581 A NO871581 A NO 871581A NO 871581 L NO871581 L NO 871581L
Authority
NO
Norway
Prior art keywords
selegiline
amantadine
weight
resp
compresses
Prior art date
Application number
NO871581A
Other languages
English (en)
Norwegian (no)
Other versions
NO871581D0 (no
Inventor
Dirk Reischig
Helmut Hettche
Wolfgang Brade
Original Assignee
Farmos Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmos Group Ltd filed Critical Farmos Group Ltd
Publication of NO871581D0 publication Critical patent/NO871581D0/no
Publication of NO871581L publication Critical patent/NO871581L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NO871581A 1986-04-16 1987-04-14 Synergistisk kombinasjon av amantadin og selegilin. NO871581L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3612702 1986-04-16

Publications (2)

Publication Number Publication Date
NO871581D0 NO871581D0 (no) 1987-04-14
NO871581L true NO871581L (no) 1987-10-19

Family

ID=6298731

Family Applications (1)

Application Number Title Priority Date Filing Date
NO871581A NO871581L (no) 1986-04-16 1987-04-14 Synergistisk kombinasjon av amantadin og selegilin.

Country Status (19)

Country Link
US (1) US4812481A (es)
EP (1) EP0241809B1 (es)
JP (1) JPS62249923A (es)
AT (1) ATE55245T1 (es)
AU (1) AU598533B2 (es)
CA (1) CA1298200C (es)
DD (1) DD259352A5 (es)
DE (1) DE3764144D1 (es)
DK (1) DK168514B1 (es)
ES (1) ES2029805T3 (es)
FI (1) FI871668L (es)
GR (1) GR3000707T3 (es)
HU (1) HU197840B (es)
IE (1) IE60245B1 (es)
IL (1) IL82216A0 (es)
NO (1) NO871581L (es)
PL (1) PL265152A1 (es)
PT (1) PT84684B (es)
ZA (1) ZA872690B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
EP0536277A1 (en) * 1990-06-25 1993-04-14 The Du Pont Merck Pharmaceutical Company Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
DE19716905C1 (de) * 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003075906A1 (en) * 2002-03-04 2003-09-18 Somerset Pharmaceuticals, Inc. Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline
EP1622450A4 (en) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2006091544A2 (en) * 2005-02-22 2006-08-31 Northwestern University Methods and compositions for modulating calcium channels
EP2201963B1 (en) 2005-04-05 2016-01-27 Yale University Glutamate modulating agents in the treatment of mental disorders
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
MX2010013393A (es) † 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE314077C (es) *
AT314077B (de) * 1972-01-07 1974-03-25 Hurka Wilhelm Verfahren zur Herstellung eines neuen, gegen den Parkinsonismus wirksamen Kombinationspräparates
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity

Also Published As

Publication number Publication date
ES2029805T3 (es) 1992-10-01
ATE55245T1 (de) 1990-08-15
DK197787A (da) 1987-10-17
FI871668A7 (fi) 1987-10-17
IE870973L (en) 1987-10-16
DK197787D0 (da) 1987-04-15
AU598533B2 (en) 1990-06-28
DD259352A5 (de) 1988-08-24
IE60245B1 (en) 1994-06-15
US4812481A (en) 1989-03-14
AU7154187A (en) 1987-10-29
NO871581D0 (no) 1987-04-14
PT84684B (pt) 1989-12-29
PT84684A (de) 1987-05-01
HUT43789A (en) 1987-12-28
PL265152A1 (en) 1988-07-07
EP0241809A1 (de) 1987-10-21
ZA872690B (en) 1988-03-30
FI871668L (fi) 1987-10-17
EP0241809B1 (de) 1990-08-08
IL82216A0 (en) 1987-10-30
CA1298200C (en) 1992-03-31
JPS62249923A (ja) 1987-10-30
DK168514B1 (da) 1994-04-11
DE3764144D1 (de) 1990-09-13
HU197840B (en) 1989-06-28
GR3000707T3 (en) 1991-10-10
FI871668A0 (fi) 1987-04-15

Similar Documents

Publication Publication Date Title
DE69426304T2 (de) Methoden zur regulation der den magen und darm betreffenden motilitaet
DE3562555D1 (en) Galenical form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion
KR890004718A (ko) 안정한 인체 단백질의 제조
BR9808285A (pt) Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus
FI86690B (fi) Foerfarande foer framstaellning av oxazafosforinloesningar.
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
Andersen et al. Reaction of the histidines of prolactin with ethoxyformic anhydride. A binding site modification.
NO882207D0 (no) Blandingskrystaller av insulin og insulinderivater, fremg. til fremst. av disse blandingskrystaller, farmasoeytiske midler som inneholder disse blandingskrystaller og deres anvendelse til behandling av diabetes mellitus.
ZA926709B (en) Pharmaceutical process
SK74995A3 (en) Antihyperglicemicly efficient pharmaceutical agents
US4879273A (en) Glucagon homologs and therapeutic use thereof
Wang et al. Cell swelling induced by the permeant molecules urea or glycerol induces immediate high amplitude thyrotropin and prolactin secretion by perifused adenohypophyseal cells
Angelucci et al. The action of caerulein on gastric secretion of the chicken
Lopez et al. Serotonin stimulates GH secretion through a direct pituitary action: studies in hypophysectomized autografted animals and in perifused pituitaries
NAKAMURA et al. Early and delayed phases of hind paw edema in rats
DK0682522T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater indeholdende vecuroniumbromid
Kolterman Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide
Saleh et al. Effect of acetylsalicylic acid and phenylbutazone on glucose absorption in vitro
FR2469179A1 (fr) Composition pharmaceutique pour injection renfermant une penicilline
Johnson et al. The preparation of an acceptable placebo for NPH insulin
HU901875D0 (en) Process for production of galenical preparations providing optimal biological accessibility of 2-hydroxi-5-methyl-laurophenon-oxim as active substance
Iacobellis et al. Renal glutaminase and carbonic anhydrase activities in potassium-deficient rats.
JPS6346160A (ja) 注射剤用容器
Fellows Local Anesthetic Activity of a Number of New Monohydrochlorides of Dialkylaminomethyl Phenyl p-Aminobenzoates.
RU2077334C1 (ru) Лекарственное средство для профилактики и лечения преждевременно увядающей кожи